An in silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessment. Am J Physiol Heart Circ Physiol 302: H1466-H1480, 2012. First published December 23, 2011 doi:10.1152/ajpheart.00808.2011.-Cell lines expressing ion channels (IC) and the advent of plate-based electrophysiology device have enabled a molecular understanding of the action potential (AP) as a means of early QT assessment. We sought to develop an in silico AP (isAP) model that provides an assessment of the effect of a compound on the myocyte AP duration (APD) using concentration-effect curve data from a panel of five ICs (hNav1.5, hCav1.2, hKv4.3/hKChIP2.2, hKv7.1/hminK, hKv11.1). A test set of 53 compounds was selected to cover a range of selective and mixed IC modulators that were tested for their effects on optically measured APD. A threshold of Ͼ10% change in APD at 90% repolarization (APD90) was used to signify an effect at the top test concentration. To capture the variations observed in left ventricular midmyocardial myocyte APD data from 19 different dogs, the isAP model was calibrated to produce an ensemble of 19 model variants that could capture the shape and form of the APs and also quantitatively replicate dofetilide-and diltiazem-induced APD90 changes. Provided with IC panel data only, the isAP model was then used, blinded, to predict APD90 changes greater than 10%. At a simulated concentration of 30 M and based on a criterion that six of the variants had to agree, isAP prediction was scored as showing greater than 80% predictivity of compound activity. Thus, early in drug discovery, the isAP model allows integrating separate IC data and is amenable to the throughput required for use as a virtual screen. computational modeling; ion channels; compound potency; QT prolongation; Torsades de Pointes arrhythmia THE CONCERN THAT DRUG-INDUCED QT interval prolongation is linked to Torsades de Pointes polymorphic ventricular tachycardia has led to the implementation of regulatory guidance documents (ICH E14 and ICH S7B) (2, 3, 43) . Following the publication of these guidelines and owing to its link with QT interval prolongation, there is an increased pressure on pharmaceutical companies to produce noncardiovascular compounds that do not affect the cardiac action potential duration (APD). Although a method that uses potentiometric dyes to record APs in ventricular myocytes generates such data more easily than conventional electrophysiological techniques (26), it is much more limited in its throughput and demand on primary tissue, and so the number of compounds that can be assessed early in the drug discovery is very limited.
THE CONCERN THAT DRUG-INDUCED QT interval prolongation is linked to Torsades de Pointes polymorphic ventricular tachycardia has led to the implementation of regulatory guidance documents (ICH E14 and ICH S7B) (2, 3, 43) . Following the publication of these guidelines and owing to its link with QT interval prolongation, there is an increased pressure on pharmaceutical companies to produce noncardiovascular compounds that do not affect the cardiac action potential duration (APD). Although a method that uses potentiometric dyes to record APs in ventricular myocytes generates such data more easily than conventional electrophysiological techniques (26) , it is much more limited in its throughput and demand on primary tissue, and so the number of compounds that can be assessed early in the drug discovery is very limited.
Although cell lines expressing ion channels (ICs) and the advent of plate-based electrophysiology devices have enabled a molecular understanding of the action potential (AP) as a means of early APD/QT risk assessment (9, 26, 27, 47) , there needs to be consensus on how to use these data to understand APD/QT risk, particularly when a compound modifies a range of mutually compensatory electrophysiological processes. Hence the requirement for assessment of a novel compound in an integrated system that articulates these multichannel implications is still very much present. Currently left ventricular midmyocardial myocytes [LVMMs; usually the repolarization of the LVMM-cell layer coincides with the end of this wave (4, 11) ] are used for in vitro AP studies to assess this. Although a high throughput AP platform is yet to be developed, there would be considerable value in being able to make full use of the early IC potencies with model-based simulations of APs that can be used to prioritize compounds likely not to fail in the later stage cell-based assays.
Since the description of the first ventricular cardiac model (5), multiple models have been published to represent different aspects of the electrophysiology of ventricular myocytes, including how drug interactions with ICs alter the electrophysiological behavior of these cells (8, 14) . Application of novel in silico approaches to assessing cardiac safety has recently received significant attention (16, 45) . In a recent article Mirams et al. (36) show that simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. We further investigated how much information the earliest stage of safety screening could give on improving the prediction of an APD risk by expanding the number of ICs integrated into the response and testing a large number of compounds. Specifically, our study examined if an in silico AP (isAP) model that uses the concentration-effect (C-E) curve data generated by the IonWorks device from a panel of five ICs that shape the ventricular AP (hNav1.5, hCav1.2, hKv4.3/hKChIP2.2, hKv7.1/hminK, and hKv11.1 that are responsible for the I Na , I Ca,L , I to , I Ks , and I Kr currents constituting phases 0, 1, 2, and 3 of the AP, respectively) could be a way to generate a prediction of compound effects on APD more easily, early in drug discovery. In particular, we set out to 1) review a number of models known to represent various characteristics of the electrophysiology of canine ventricular myocytes (for review see Ref. 14) with the purpose of assessing their applicability to this investigation, 2) fit/calibrate the model of choice to in-house experimental conditions (e.g., breed of dog), and 3) determine the ability of the isAP model to accurately predict the APD changes to LVMM cells of a test set of 53 compounds (reference and AstraZeneca proprietary compounds) selected to cover a range of IC profiles and blinded to the model. . AP experiments were performed on isolated LVMMs that were isolated enzymatically from the left ventricular midmyocardium of the heart as described previously (1) and stored at room temperature in standard myocyte Tyrode solution.
MATERIALS AND METHODS

Isolation of
Conventional sharp-electrode. Transmembrane potentials were recorded from isolated LVMMs at physiological temperature as described previously (1) . Briefly, APs were recorded with a glass micropipette (3 M KCl; 20 -40 M⍀) that was connected to the headstage of a MultiClamp 700A amplifier (Molecular Devices) and acquired using pCLAMP software (Molecular Devices). AP stability was assessed in the first 5-10 min of recording in the standard Myocyte Tyrode solution at a cycle length of 1 s in the standard myocyte Tyrode solution. Rate adaptation was investigated by changing the cycle length in the following sequence; 1, 2, and 1 s, ensuring steady state was achieved at each cycle length before changing to the next cycle. Following exposure to the standard Tyrode solution, the same sequence was repeated during perfusion of the same preparation with standard Tyrode solution containing vehicle (0.1% DMSO). In an additional set of experiments, variation in APD adaptation (i.e., resulting from changes in cycle length for a range of 0.25-5 s) was investigated and cycle length was only changed once any alteration in APD evoked by the prevailing cycle was at steady state. APD at 90% repolarization (APD 90) was measured as described (1) . These vehicle AP data generated during a period of 2 years were used to refine the isAP model, so it is able to capture the morphology of the AP measured in our LVMM cells.
Epifluorescence recordings. The equipment set-up for epifluorescence recordings using di-4-ANEPPS was identical to that described previously (26) . APs were evoked by electrical field stimulation at 1-s cycle length, and illumination with UV light was restricted to 5 seconds every 4 min to limit photodamage, at which time AP measurements were recorded at physiological temperature for each experimental condition. Following exposure to standard myocyte Tyrode solution, then standard myocyte Tyrode solution containing vehicle (0.1% DMSO), cumulative C-E curves to a compound were constructed over the nominal concentration range. A 24-min period was required to test four concentrations for most of the test set of 53 compounds, although 28-and 32-min periods were needed to test 11 compounds at five concentrations and one compound at six concentrations. APD 90 was measured as described in Hardy et al. (26) . Experimental condition (e.g., perfusate solution) was changed every 4 min. Fluorescent data were acquired directly to hard disk using a Digidata 1322A computer interface and pCLAMP software and sampled at 10 kHz. APD data were averaged from five traces. Any drug effects were compared with data in the presence of vehicle (0.1% DMSO).
IonWorks and concentration-effect curves. The conditions under which the Chinese hamster ovary K1 cells expressing hKv11.1 (hI ERG), hNav1.5 (hINa), hKv4.3/hKChIP2.2 (hIto), hKv7.1/hminK (hIKs), and hCav1.2 (hICa) were cultured and their preparation for IonWorks are briefly explained in Table 1 , which also shows the voltage protocols, solutions, positive controls, and serial dilutions used to generate IonWorks-based potency estimates. All recordings were made at room temperature. These estimates were for effects on the peak of hI ERG, hIKs, hINa, hIto, or hICa currents. IonWorks data were either IC50 or EC50 value from one or more runs (Table 3) . For each run, a noncumulative 8-point C-E curve was produced and an IC 50 or EC50 value was determined, with data for a given concentration of compound being from between 1 and 8 cells. When two or more runs were performed then the data were merged before fitting a Hill curve from which a single IC 50 or EC50 value was derived. Data were normalized to vehicle, and the differences between vehicle and top concentration tested were assessed for statistical significance using the Student's t-test and showing greater than 25% change from control (being the amount needed to observe a difference beyond the experimental noise). Where an antagonistic effect was observed with a compound, the data were then fitted to a simple pore block model using the Hill equation (8) , allowing the Hill coefficient to vary but assuming that the compound would eventually cause complete block of the channel (i.e., I max in Eq. 1 equal to Ϫ1). In the instance of agonists, the maximum agonistic effect was not constrained (i.e., I max in Eq. 1 Ͼ 1). In all cases, I 0 defines the amount of current in the presence of vehicle (0.1% DMSO) only. The equation of the Hill curve was used to simulate the compound effects at different concentrations.
Simulations. The isAP model is based on a canine epicardial model described previously by Hund and Rudy (30) and adapted for midmyocardial cells as described by Benson et al. (6) . Models were downloaded and converted into MATLAB (The MathWorks, Natick, MA) format using the Cellular Open Resource (http://cor.physiol.ox. ac.uk/) (20) . Model code is provided as a supplemental file (and additionally in SBML format). All simulations were performed in MATLAB on a 16 node server using a commercial ODE solver ODE15s, which is based on the numerical differentiation formulas. The solver uses an adaptive time-stepping method in which the maximum timestep allowed was 0.1 ms. Virtual cumulative C-E curves to a compound were constructed over a concentration range of 0.001-30 M. When simulating the effect of compounds using data from IonWorks assays against any of the five ICs, the effect at a concentration [D] was modeled by scaling the conductance of those channels as defined by Eq. 1:
). Simulated APD90 was calculated as follows and similar to that used for epifluorescence recordings (26) . The peak of the AP was calculated from the peak of the dome of the AP if this was there and the peak of the upstroke if not. Amplitude of the AP was calculated as the difference between this peak value and the resting membrane potential. APD90 is the time taken from the upstroke to when this amplitude value had decreased by 90%. APD90 for vehicle (0.1% DMSO) and drug conditions were determined by simulating a train of five consecutive simulated AP and using the APD90 from the fifth AP. Any drug effects were compared relative to data in the presence of the simulated vehicle AP trace of each model variant. Prediction of whether a compound causes a prolongation (P), shortening (S) or no-effect (NE) at top experimental concentration was compared to a single high concentration prediction at 30 M simulated concentration. This latter concentration is routinely the top test concentration used for IC screen in our laboratories.
Model optimization. To fit the model to each of the 19 0.1% DMSO SE traces, an optimization procedure that minimized the root-meansquare-deviation between model and experimental APs in the range t ϭ 0 ms and t ϭ 100 ms (capturing the notch and height of the dome) and t ϭ 250 ms and t ϭ 500 ms (capturing the end of the AP) was performed. The optimization algorithm used in this study is the MATLAB fminsearch algorithm, which is the simplex search method by Lagarias et al. (33) . No upper bounds on the scaling values were imposed. A lower bound of zero was set for all except INa current, for which the lower bound was 0.5 to ensure a significant upstroke was obtained.
Solutions and drugs. For sharp-electrode and epifluorescence recordings, the standard myocyte Tyrode solution contained (in mM) 145 NaCl, 4 KCl, 1. Cells purchased from Millipore were grown in Iscoves nutrient mixture and Glutamine supplemented with 10% FCS, 400 g/ ml geneticin, 100 g/ml hygromycin, 2% HT supplement (50ϫ), and 1% nonessential amino acids (100ϫ). Cells used in the IonWorks were incubated at 37°C for 48 h. Cells expressing hCav1.2(hICa)
Cells purchased from Chantest Corporation were grown in Ham's F-12 nutrient mixture and L-glutamine supplemented with 10% FCS, blasticidin (10 g/ml), geneticin (G-418, 400 g/ml), hygromycin (250 g/ml), penicillin-streptomycin (100 units/ml; 100 g/ml), and zeocin (75 g/ml). Twenty-four hours before assay cells were induced with doxicycline to a final concentration of 1 g/ml and incubated for a further 6-8 h at 37°C. 
Cells expressing hICa
After the monolayer of cells was washed with PBS, cells were detached with accutase and centrifuged at 1,100 g for 2 min. The supernatant was discarded and the remaining pellet of cells was resuspended in HBPS containing 10 mM BaCl2 (HBPS ϩ Ba) to a concentration of 1.5 million cells/ml. Measurements of currents hIERG A holding potential of Ϫ70 mV was applied for 20 s, followed by a 160-ms step to Ϫ60 mV (allowing an estimated leak current to be measured), and a 100-ms step back to Ϫ70 mV. The voltage was then stepped to ϩ40 mV for 1 s and a steady-state current was observed. A 2-s step down to Ϫ30 mV, inducing the tail current, was then followed by a 0.5 s step to Ϫ70 mV. hIKs
The voltage protocol consisted of a 5-s period holding at Ϫ80 mV, a 100-ms step toϪ100 mV (to measure an estimated leak current), a 100-ms step back to Ϫ80 mV, followed by a 4-s step to ϩ40 mV, a 300-ms step to Ϫ40 mV, and finally a 200-ms step to Ϫ80 mV. hINa and hIto 4 The voltage protocol consisted of a 15-s period holding at Ϫ90 mV, a 160-ms step to Ϫ100 mV (to measure an estimated leak current), a 100-ms step back to Ϫ90 mV, followed by 10 pulses each for a duration of 50 ms applied at 3 Hz. The first eight 50-ms pulses were to Ϫ20 mV and the ninth and tenth pulses to ϩ20 mV. 300 ms after the tenth pulse there was another longer pulse to ϩ20 mV (1 s) with a final 300-ms step to Ϫ90 mV. hICa A holding potential of Ϫ65 mV was applied for 10 s, before depolarizing to 0 mV for 500 ms and a steady-state current observed. Solutions hIERG, hIKs, hINa, and hIto
The internal solution was composed of (in mM) 100 K-gluconate, 40 KCl, 3.2 MgCl2, 3 EGTA , and 5 HEPES (pH 7.3 using 1 M KOH). The access solution was composed of (in mM) 140 KCl, 1 EGTA, 1 MgCl2, and 20 HEPES (pH 7.3 using 1 M KOH), and 100 g/ml of amphotericin B. PBS contains (in mM) 136.9 NaCl, 2.7 KCl, 8 Na2HPO4, 1.5 KH2PO4, 0.9 CaCl20.2H2O, and 0.5 MgCl20 ⅐ 6H2O. hICa Similarly to the other four currents, same internal solution was used.
The access solution was composed of (in mM): KCl 140, EGTA 1,2 Cells were described by Persson et al. (40) and (41), respectively. All cells were grown to semiconfluence at 37°C in a humidified environment (5% CO2). 3 When performing the CHO-hINa/CHO-hIto duplex assay, the cell counts were determined and the cell concentration for both cell suspensions was adjusted to 1 ϫ 10 6 cells/ml. The cells were mixed together to attain a 60:40 ratio hINa:hIto. A single voltage pulse was applied to evoke the pre-and postcompound currents, and the degree of inhibition or stimulation was assessed by dividing the postscan current by the respective prescan current for each well. 4 The degree of response for hINa current was assessed for both the first and eighth pulses, while the effect on hIto was assessed for the eleventh pulse.
of them are activators), 12, 20, and 19 (4 of them are activators) compounds selected for this investigation show activity (IC 50 value Ͻ30 M) against hKv11.1, hKv7.1/hminK, hKv4.3/hKChIP2.2, hNav1.5, and hCav1.2, respectively. Additionally, 16 out of these 53 compounds were found to be selective inhibitors and active against only one IC and 12 of the panel were found to have activity against more than four ICs. Reference compounds and chemicals were purchased from Apin Chemicals (Oxon, UK), Calbiochem (Darmstadt, Germany), Tocris Bioscience (Bristol, UK), and Sigma-Aldrich Company (Poole, UK). On each experimental day, each compound was formulated as a DMSO stock that was then serially diluted in DMSO to give three further DMSO stocks (in mM). Finally, each of these stocks was diluted 1,000ϫ in standard myocyte Tyrode solution to give the final test concentrations.
For IonWorks. All solutions, positive controls, and serial dilutions are shown in Table 1 .
Statistical analysis. Because each dog heart yielded many LVMMs, it was possible to study more than one drug following each isolation. However, it was not necessarily possible to complete all the testing required on a drug in a single isolation. Thus a given drug may have been tested on six LVMMs, but four came from one dog and two from another dog. In this circumstance, the data are considered n ϭ 6 and in Table 3 the replicates information is expressed as n(dogs) ϭ 6(2). Averaged data are mean Ϯ SE. Differences were tested for statistical significance using the paired (2 sample for means; same compound) Student's t-test. A value of P Ͻ 0.05 was considered significant. (17); Hund-Rudy (HR04) model (30) , which has been modified to represent a mid-myocardial cell (6); Greenstein (G06) model (24); Flaim (F06) model (15) ] were reviewed to assess their applicability to this study by visualizing the similarity of the simulated AP to the morphology seen within the sharp-electrode (SE) LVMM AP recordings at 1-s cycle length. It was found that the HR04 model compared most favorably out of all models with the mean of the SE data (e.g., similar resting membrane potential and APD) (Fig. 1A ) and forms the model used for this study.
RESULTS
Model selection and generation of a model ensemble. A number of AP models [Winslow (W99) model (55); Fox (F02) model
Published models have been calibrated to experimental data obtained from different laboratories and breeds of dog. To reduce this heterogeneity, it was essential that the isAP model captures the morphology of the AP recorded with SE method in canine LVMM cells. Comparison of SE recordings from 19 different dogs all treated with 0.1% DMSO vehicle control showed variation, particularly in APD (Fig. 1B) . Less variation was observed between cells taken from the same dog (data not shown). Rather than use a mean or representative AP, this variation within the isAP model was captured by using an ensemble of initial parameter sets (variants) that were able to accurately describe each of the SE AP traces from the 19 dogs.
It was assumed that the variation in AP morphology seen between the experimental traces is due to physiological variability that can be captured by parameters within the model. Specifically, it was initially assumed that the inter-dog variability was due to the variation in the membrane densities of four ICs [I Kr (rapid delayed rectifier K ϩ current), I to1 (4AP-sensitive transient outward K ϩ current), I Na (fast Na ϩ current), and I Ca,L (L-type Ca 2ϩ current)] and that this density influenced total conductivity through each channel. This is consistent with the experimental data that shows variation of channel density between different cells (Fig. 2, B-D) . Thus each individual AP trace was fitted by scaling the conductance of these ICs by the parameter: D x (e.g., see Table 2 , columns 1-4). However, initial parameter ensembles were unable to Table 2 ). C and D: mean % change in AP duration at 90% repolarization (APD90) for best fit of the isAP model (with the IKr structure taken from the F02 model and also varying the constant, Cto1) and experiment as a function of drug concentration for dofetilide and diltiazem, respectively. The mean isAP model prediction line (bold red line) corresponds to the mean of the % change in APD90 from the 19 models (dashed red lines). The mean data line (black solid line) for experiment is the mean of the % change in APD90 for each cell from where all cells are from the same dog (dashed black lines). Error bars represent SE across the 19 different parameter sets in the case of model and across 6 cells (2 dogs) and 7 cells (2 dogs) for dofetilide and diltiazem, respectively, in the experimental case.
sufficiently match the calibration set of SE recordings and so also considered as an option was to increase the current flowing through the I Ks channel (slow delayed rectifier K ϩ current). However, because this current is known to be extremely low in LVMM cells (6) , it therefore should not be allowed to have a prominent role in the AP. Consequently, the value of the I Ks conductance was fixed and other possible densities that could be altered to supplement the initial four parameters were explored by carrying out a local sensitivity analysis on parameters to changes in APD at 30% repolarization and APD 90 to Table 2 ). achieve a quantitative agreement between the simulation and calibration data. The results of the sensitivity analysis indicated that the conductance values of the sarcolemmal Ca 2ϩ pump (I p,Ca ) and background Ca 2ϩ current (I Ca,b ) could be included in the model optimization as were the conductance values of I NaK (Na ϩ -K ϩ pump), pow (power to which the "d" activation gate of the I Ca,L channel is raised), I NaCa (Na ϩ -Ca 2ϩ exchanger), I NaL (these were chosen to improve the fit to the duration of the AP while maintaining good fits to the pharmacological effects associated with dofetilide and diltiazem), and I K1 (time-independent K ϩ current; I K1 was chosen to help improve the fit to the end of the AP), and finally to improve the quantitative fit, varying of the constant, C to1 , in the formulation of the time-independent rectification gate for I to1 current was explored (Table 3) .
Initially it had been assumed that compounds with a known effect on I Na current in IonWorks blocked only the peak I Na current and not the late I NaL current. However, a considerably For each ion channel (IC), 4 -8 cells were tested per compound per run and concentrations were spaced at eight half log10 intervals. However, for some compounds, multiple runs were completed, and so the number of cells tested was greater than this.
better performance of the model in predicting effect on the AP was found when the same C-E curve and Hill coefficient was applied to both currents; this is consistent with at least some compounds where a measurement of both peak and late I Na currents have been made (42) . Although these subsequent parameter ensembles were able to mimic the experimental APs in shape and duration (Fig. 1B) , they failed to capture the magnitude of effect when subsequently challenged with a simulated drug, using either dofetilide (a hKv11.1 blocker) or diltiazem (a hCav1.2 blocker). Therefore, the base model was further adapted to replace the existing formulation with the outward K ϩ channel formulations described by Fox et al. (17) . This adaptation was necessary for the purpose of removing a prolongation artefact observed with mild simulated blockade of the hCav1.2 channel with respect to experimental observations. As a result, it was necessary within the model optimization procedure for the parameter ensemble to reproduce dofetilideand ditiazem-induced APD changes as well as fitting to the morphology of the AP. Although not explicitly represented in the objective function, it was critical to ensure that the variation in parameters that were introduced as a result of the optimization procedure were consistent with the observed variation in both APD 90 adaptation (i.e., resulting from changes in cycle length) and in the individual IC current-voltage relationships (Fig. 2) . Figure 1 , B-D, demonstrates the results of this fitting for a set of variants ( Table 2 ) that were able to capture AP morphology, drug-induced APD effects and show good agreement to APD 90 -rate dependence and current-voltage relationships. This ensemble of parameters therefore was selected as the model for which subsequent predictions were to be made.
isAP predictions for hK V 11.1 and hCa V 1.2 blockers. The isAP model has been fitted on canine LVMM APs both in the absence of pharmacological intervention and in the presence of dofetilide and diltiazem. Thus an immediate but undemanding form of validation was to test the performance of the model on two different hKv11.1 or hCav1.2 inhibitors. We used E-4031 (a hKv11.1 blocker; Fig. 3C ) and nifedipine (a hCav1.2 blocker; Fig. 4C ) to verify whether the data support the hypothesis that these two compounds would act identically to the training compounds (dofetilide and diltiazem). Predictions of the model at a high simulated concentration of 30 M were compared with top experimental concentration tested (35 compounds were tested at Ն30 M). For E-4031, the model predicted an AP prolongation (Fig. 3B) that reached a plateau beyond 1 M (Fig. 3D) , an observation consistent with experimental data (Fig. 3, A and D) . Additionally, the model predicted nifedipineinduced shortening of the AP (Fig. 4, B and D) and a complete loss of the AP dome (Fig. 4B ) consistent with increasing blockade of the hCav1.2 channel, observations consistent with experimental data (Fig. 4, A and D) . Whereas at a 30 M simulated concentration a more pronounced shortening of the AP was observed compared with the top experimental concentration of 3 M, a more quantitative agreement was seen at a simulated concentration of 3 M (Fig. 4D) .
isAP predictions of compounds with activities against multiple ion channels. To avoid unnecessary rejection of potentially valuable compounds that affect multiple ICs, an integrated approach based on simulation of their effects on the AP may help to improve prediction of their potential to evoke/not evoke changes in APD. Therefore, a considerably more stringent test of the model was to evaluate its predictions for compounds that have different activities against multiple ICs. Pimozide, a multiple IC blocker, inhibited hKv11.1, hNav1.5, and hCav1.2 channels (Fig. 5C) . The model predicted a shortening of the AP and complete loss of the dome morphology ( Fig. 5B) , an observation consistent with experimental data (Fig. 5A) . Additionally, both experimental and simulated data show that pimozide induced an initial prolongation of the AP due to hKv11.1 blockade and subsequent shortening at higher concentrations, likely due to a combined blockade of hCav1.2 and hNav1.5 channels (Fig. 5D ). However, a left shift was observed when comparing experimental versus simulated APD changes evoked by pimozide (Fig. 5D ). This left shift effect was observed for a number of other compounds, by unknown mechanisms, and provided the rationale for using a more qualitative analysis of the predictions. Moreover, AZ32, another multiple IC blocker, inhibited hKv11.1, hKv4.3/ hKChIP2.2, and hKv7.1/hminK channels (Fig. 6A ). In contrast with pimozide, both experimental and simulated data show that AZ32 prolonged the AP at similar concentrations (Fig. 6B) . Furthermore, experimental APD data obtained with AZ37, another multiple IC blocker with similar potencies against hKv11.1 and hNav1.5 channels, suggest that blockade of hNav1.5 had protected against an APD prolongation that might be caused by the inhibition of the hKv11.1 channel (Fig. 6, C  and D) . This absence of effect on APD was also predicted by the model (Fig. 6D) . Finally, the model was able to predict the effects of multiple IC modulators. For example, Fig. 6E shows that AZ7 inhibited hKv4.3/hKChIP2.2 and stimulated both hKv11.1 and hCav1.2 channels. Experimental and simulated APD data show that AZ7 had no effect at lower concentrations (likely due to a combined modulation of the 3 ICs), whereas at higher concentrations it induced an APD decrease likely due to its stimulatory effect on the hK V 11.1 channel (Fig. 6F) .
Scoring the isAP model against a test set of 53 compounds.
A framework for assessing the quality of the isAP model predictions for the test set of 53 compounds (Table 3) was applied by scoring the sensitivity, specificity, and predictivity as recently described by Valentin et al. (50) . This methodology is applicable to this work since a clear endpoint (e.g., P, S, or NE) in both the model and experiment with comparable concentration ranges was assessed. It has been proposed that an overall predictivity of 65-74% is considered sufficient, 75%-84% good, and greater than 85% is considered excellent (22) . Additionally, the results of the sensitivity and specificity calculations may determine where the isAP model can be aligned with a specific phase in the drug discovery and development process. Because each prediction made by the model has to be an ensemble of 19 predictions, there was the added decision requirement of adjusting a threshold of variants as to when a compound would be considered to be either a prolonger or shortener. Thus one of the key aspects of the model would be its ability to assess how the effect of compounds may vary between different animals. Experimentally, it would be impractical to repeat the experiment 19 times in 19 different dogs. However, because the model has been trained to SE traces from 19 dogs, it has the capability to predict what the outcome might have been, had that compound have been tested in each dog. Figure 7 shows the impact of changing the threshold of variants on the sensitivity, specificity, and predictivity scores. The threshold value to be selected should be a balance between keeping the model sensitive, yet using a sufficient number of variants to build confidence to the end-user. A value of any six of the variants was selected to retain adequate sensitivity in the model so it can be used earlier in drug discovery as identification of a hazard, yet balancing the threshold to provide suitable specificity and predictivity. Assessment of the model was carried out by first comparing the mean percent change in APD 90 between the model C-E plots and those obtained experimentally. If the plots were within 15% of each other at all of the experimental concentrations tested then the model was considered to be in quantitative agreement and its prediction was therefore considered as either a true positive (TP) or true negative. Up to 15% difference in the percent change in APD 90 between the model and experiment was permitted since this is the value for which the compounds (dofetilide and diltiazem) used in the calibration were considered to be in quantitative agreement with the model. Forty-five percent of compounds used in this investigation were in quantitative agreement; however, it was observed that many compounds [e.g., pimozide (Fig. 5D) ], whereas not quantitatively in concordance showed a qualitative agreement. Therefore, a subsequent comparison was of whether the compound caused P, S, or NE between the top experimental concentration tested and a high concentration prediction in the model (e.g., 30 M). The results of these comparisons are presented in Table 4 . For the purpose of defining the scores of the model for sensitivity, specificity, and predictivity, two methods of scoring were used based on the level of information required for the compound. The first method scores the model for its ability to provide predictions for whether the compound causes a change in APD 90 greater than 10% and additional information regarding the direction of this change (e.g., P or S) (Table 4 and Fig. 7A) . A second method scores the model for simply providing a prediction as to whether a compound is active (e.g., greater than 10% change in APD 90 ; Table 4 and Fig. 7B ). Table 4 shows that the model predicted the activity of some compounds, but it was incorrect in predicting the direction of change in APD 90 . These compounds are called false positive, although the second method of scoring considers these instances as true positives (TPs) ( Table 4) . Applying the first method of scoring, sensitivity, specificity, and predictivity of the model were found to be 78%, 58%, and 68%, respectively. On the other hand, when using the second method, which queries whether a compound is likely to be active or inactive, the model was found to be 82% sensitive, 79% specific, and 81% predictive.
DISCUSSION
Because the cost of getting a compound to the market escalates exponentially through the drug discovery process (38) , it is critical to deselect compounds carrying a QT prolongation risk as early as possible (35) . If confirmed in the Thorough QT/QTc study, this hazard can lead to substantial development implications. Companies have therefore developed testing strategies (for example, conducting IC screens, LVMM AP, and ECG studies) to predict and remove the risk of compound changing the QT interval (43, 51) . Given that by the use of current AP assays (1, 26) , the number of compounds that can be assessed early in discovery is very limited. Application of a computational approach at a stage in the drug discovery phase where there are many compounds to choose from may not only reduce the demand for carrying out the primary cell AP assays (e.g., this is consistent with our commitment for replacing, reducing, and refining animal testing) but also allow for more cost-and resource-efficient design of compounds with improved safety profile (13, 16) . In a recent article Rodriguez et al. (45) suggested the potential need to prepare/rebuild models for the assessment of pharmacological safety. As anticipated, our study shows that it was necessary to rebuild the Benson et al. model (6) for the assessment of drug-induced APD change (see Fig. 1 and Table 2 ). Although an improved version of the dog epicardial HR04 model (12) has been shown to yield AP simulations that are similar to experimental data for different pharmacological interventions Fig. 7 . Impact of threshold level for number of model variants required to demonstrate compound effect for making prediction as to whether a compound causes a change in APD90 greater than 10%/the direction of this change (e.g., P or S) (A) and is active (B). Vertical red line corresponds to a cut-off of 6 variants. Pred, predictivity; Sens, sensitivity; Spec, specificity. Concentrations for AP experiments were spaced at either 4 or 5 half or full log10 intervals. Two criterions had to be met for a compound to be considered P or S (e.g., a change in action potential duration at 90% repolarization (APD90) Ͼ10% and a statistical significance). Scores were obtained with a cut-off of 6 variants for predicting either prolonger/shortener or active/inactive. For predicting either prolonger/shortener or active/inactive, 6, 11, 15, and 21 or 6, 4, 15, and 28 compounds were found to be false negative (FN), false positive (FP), true negative (TN), and true positive (TP), respectively. For predicting either prolonger/shortener or active/inactive, specificity (ability to detect TN compounds), sensitivity (ability to detect TP compounds), and predictivity (proportion of TPs detected) were found to be either 58%, 78%, and 68% or 79%, 82%, and 81%, respectively. See Valentin et al. (50) for confidence in prediction calculations. AP, action potential; NE, no effect; P, prolongation; S, shortening; NS P Ͼ 0.05, *P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001 vs. from vehicle (0.1% DMSO).
[ (7) and Mirams et al. (36) by training the isAP model to match in vitro changes in APD, expanding the number of ICs to five integrated into the response and increasing the validation space to 53 compounds. Moreover, the C-E curve dataset used in this study were generated from one source using the IonWorks device, and as such the associated variations inherent in the dataset were considerably minimized. In addition, the model of drug block in this study was improved by measurement of C-E curve Hill coefficients. Three additional features differentiating the isAP model from existing AP models are: 1) variability in APD from preparation to preparation was taken into consideration, 2) integration of data on multiple IC modulators (e.g., inhibitors and stimulators of IC activities) and not only inhibitors, and 3) its predictions were scored against changes observed in measured APD rather than Torsades de Pointes observations (36) . This latter feature has allowed evaluation of the predictive value of the isAP model. Therefore, the data collected from the isAP model were compared with the experimental outcome using three quality-related parameters: sensitivity, specificity, and predictive capacity. To predict whether a compound is likely to be active or inactive, the isAP model was found to be 82% sensitive, 79% specific, and 81% predictive. Thus the overall predictivity of the isAP model is considered good (see Ref. 22) . This isAP overall predicitvity is reduced to sufficient when the change of direction (P vs. S) was to be predicted (sensitivity, specificity, and predictivity were found to be 78%, 58%, and 68%, respectively). Because it is better to identify and eliminate AP hazard during the early drug discovery phases, in silico AP models to be used during these phases should be highly sensitive (e.g., have a high confidence in detecting TPs with a low rate of false negative to minimize the risk of progressing new compounds with known AP liability) (50) . Because this fits well with the sensitivity described for the isAP model, the latter should be used during Lead Identification and Lead Optimization phases (51) along with the generation of the IonWorks IC data. For new compounds that do not show activities against the five ICs, there will be no need to use the isAP model, which is expected to predict no changes in APD. However, for those compounds showing activities against different ICs, the isAP model should be used to 1) develop structure-activity relationship during Lead Identification and early Lead Optimization with the aim of getting compounds with no IC concern and 2) help select during late Lead Optimization one or more short-list of compounds with IC concern and test them for cardiovascular liability in vivo before the preclinical investment decision. Because the isAP simulations can be computed upon completion of IC screens and the throughput, based on a routine usage of a MATLAB distributed computing server, is greater than 200 compounds per hour, this isAP model is amenable to the throughput required for use as a virtual screen. Furthermore, quantitative structure-activity relationship IC models are currently being applied to correlate structural or property descriptors of compounds with potencies against ICs (21) . Hence, medicinal chemists, after an appropriate validation of the isAP model, can likely in the future use both the potency estimates produced by the quantitative structure-activity relationship IC models (with the limitation of using simple block by fixing the coefficient of Hill) and the isAP model to predict compound-induced changes in APD during Target Identification phase.
Although the repolarization of the LVMM-cell layer usually coincides with the end of the T wave (4) (see also Ref. 39) and data from these myocytes may better relate to QT measurements, the isAP model may not accurately predict whether a compound is likely to have an effect on the QT interval since changes in this interval can be influenced by many other factors (for example, but not exclusive to, heterogeneity of the left ventricular wall, systemic circulation, signals from the central and the autonomic nervous systems, etc.) that are not taken into consideration when performing this one-dimensional isAP analysis. Additionally, the easy access to large compound databases by the pharmaceutical industry/regulatory bodies and the significant progress recently seen in the field of cardiac modeling [for example this study and other recent works performed in academia and industry in collaboration with regulators, e.g., preDiCT (http://www.vph-predict.eu/); 16] and TI PHARMA (http://www.tipharma.com) projects, which aim to develop the computational infrastructure necessary for in silico simulation, and ultimately accurate prediction, of the impact of drug candidates on cardiac electrophysiology and induction of arrhythmias, would be of great assistance to initiate a truly collaborative commitment to determine how well AP potential models predict changes in the QT interval and produce a well-validated ECG model with the proper translation of preclinical safety findings with potential clinical QT concerns (23, 45) .
This work is the first example of using an ensemble of model variants to give a better indication of the how compound effects may vary within in a population (e.g., limited in this study to healthy dogs). However, although only the effects between different dogs are represented, rather than within a set of cells taken from the same animal, we deliberately chose to do so to represent the larger source of experimental variation (e.g., inter-dog rather than intra-dog). There is continued need to extend this ensemble set to supplement the isAP model predictions to reflect on whether the effect of a compound on APD may be seen only between dogs, rather than across different cells. Additionally, it would be informative to extend this ensemble to have an improved representation of a broader population, e.g., to include genetic disposition and disease, that take into account changes in IC expression and function, such as in heart failure. In this study, the ensemble of 19 parameter sets was created by fitting to vehicle AP traces from 19 different dogs and to the effects of dofetilide and diltiazem. It is conceivable that there may be equally valid parameter sets that satisfy the objective function; yet there is a need for additional data (ideally from the same compounds) that may help to further constrain the available model parameterization.
For example, this data may include experiments that measure the effects of fast and slow changes in the pacing frequency or the subsequent effects on cellular contraction. In doing so, we anticipate an even more robust model that provides additional functionality to the predictions.
Limitations. For our one-dimensional AP simulations, the effect of a drug was simply represented as a change in conductance. Although the isAP model still shows a good ability in the prediction of APD risk, compounds with similar potencies against ICs will perform similarly in the isAP model despite observing more diversity on the APD experimentally. Therefore, more complete modeling of the state-based interaction between IC and drug (e.g., voltage dependence, statedependence, and allosteric effects) has to be considered in future studies to assess whether this results in improving the specificity and sensitivity of the isAP model. Data from a recent study suggest that two-dimensional analysis may be sufficient to deal with the difficult problem of rate-dependent effects of class I antiarrhythmic drug-block (37) . In addition to this, an ongoing study in our laboratory is being conducted to overcome this limitation by developing multi-state IC models, integrating these new IC models into the isAP model, and assessing the effects of new compounds and those used in this study in subsequent versions of the isAP model. Because both our experimental and numerical studies were performed in isolated cells and like many other studies they fall short in accounting for any coupling and spatial effects, which can dramatically alter the AP shape and duration (10, 12) , data derived from this study should be considered as a first approximation. Therefore, future tissue studies to be conducted have to assess the impact of electronic interactions on the AP predictions (see Ref. 44) .
Finally, a left-shift effect between experiment and model predictions was observed for a number of compounds (e.g., pimozide; Fig. 5D ) and hence qualititative predictions are being provided rather than quantitative. Potential causes that may partly explain the observed left-shift can be, but not limited to, 1) limitations of the IonWorks plate-based electrophysiology device. For example, as a consequence of compound adsorption issues (25, 48) , the potency of a compound against an IC can be underestimated. Additionally, the device can only operate at room temperature. Bearing in mind the reported effects of temperature on hERG pharmacology (32) and electrophysiology (53), we cannot exclude the possibility that at physiological temperatures, differences in the effects of compounds on the AP could emerge; 2) IC subunit composition and the extent to which a stable cell line reflects the native state; and 3) lack of incorporating the effects of compounds on other ventricular ICs, G protein-coupled receptors, and kinases in the isAP model. For example, neither the isAP model (data not shown) nor the LVMM cell (31) predict an APD prolongation in the presence of an inhibition of the hKv7.1/hminK current, even though one might expect an effect in vivo (19, 54) . This is likely caused by the failure of AP shortening, due to the inhibition of ␤-adrenergic-sensitive hKv7.1/hminK current. Future approaches should investigate the ability of the isAP model to reiterate this feature of the hKv7.1/hminK current on APD by utilizing a recent model of ␤-adrenergic signaling in the ventricular myocyte (28) . Thus coupling these effects to experimental measurements would provide further understanding of the likely cardiac impact and may help in getting an AP model that mimics better the native state. Equally, and in agreement with recent discussions on the concept of Systems Pharmacology (52) (see also Refs. 18, 29, and 34), inclusion of pharmacokinetic/pharmacodynamic representation (e.g., changes to the clearance properties of the compound or IC trafficking/expression and cardiac accumulation) into the isAP model may also improve our predictions, particularly for the purpose of translating APD predictions to changes in the QT interval.
Conclusions
The results of the present investigation suggest that this isAP model allows integrating separate IC data and producing virtual C-E plots beyond what is feasible experimentally for better evaluation of whether compounds pose a risk to affect the cardiac AP during the early drug discovery process and before substantial resource has been invested. Finally, the present results show promise for in silico models to add value to preclinical cardiac risk assessment and be integrated into the pharmaceutical industry as well as with the regulatory agencies.
